Hematology | Topics

Future Directions in Graft vs Host Disease Management
September 20, 2022

Closing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.

Treatment Armamentarium for Chronic Graft vs Host Disease
September 13, 2022

Comprehensive discussion on the pharmacologic treatment armamentarium available for patients with chronic graft vs host disease.

Optimal Staging Strategies for Chronic Graft vs Host Disease
September 13, 2022

Expert hematologist/oncologists highlight challenges in staging chronic graft vs host disease and share strategies to optimize cGHVD assessment.

Scenario 2: A 59-Year-Old Woman With Chronic GVHD
September 06, 2022

After reviewing a clinical scenario of chronic graft vs host disease, panelists consider the importance of different allogeneic transplant types.

Selecting Therapy for Patients With a Partial Response to Frontline Therapy
September 06, 2022

Shared insight on treatment approaches toward patients with acute graft vs host disease who experience partial response to frontline therapy.

Selecting Optimal Therapy for Acute GVHD
August 30, 2022

Focusing on pharmacologic options, expert panelists review frontline treatment strategies for patients with acute graft vs host disease.

Biomarkers for the Prognostication of Graft vs Host Disease
August 30, 2022

Expert hematologist/oncologists share their perspectives on use of biomarkers to help prognosticate graft vs host disease.

Alexis A. Thompson, MD, MPH, Considers Future Assessments of Beti-Cel in β-Thalassemia
August 26, 2022

Alexis A. Thompson, MD, MPH, reviewed the unmet needs of patients with β-thalassemia who will receive betibeglogene autotemcel.

FDA Grants Approval to Pemigatinib for FGFR1 Rearranged Relapsed/Refractory Myeloid/Lymphoid Neoplasms
August 26, 2022

Pemigatinib had been approved by the FDA as a treatment for patients with FGFR1 rearranged relapsed/refractory myeloid/lymphoid neoplasms.

FDA Approves Ibrutinib in Pediatric Patients With Chronic GVHD
August 24, 2022

Based on results of the phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for pediatric patients with chronic graft-versus-host disease.